Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: The case of antipsychotics

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 2, 2005, Pages 151-161

  Calderone, Vincenzo ^a   Testai, Lara ^a   Martinotti, Enrica ^a   Del Tacca, Mario ^a   Breschi, Maria Cristina ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLARITHROMYCIN; CLOZAPINE; DOXEPIN; DROPERIDOL; ETHYLHEPTYL[4 (4 NITROPHENYL)BUTYL]AMINE; FLUOXETINE; HALOPERIDOL; N METHYL N [2 [METHYL(1 METHYL 1H BENZIMIDAZOL 2 YL)AMINO]ETHYL] 4 [(METHYLSULFONYL)AMINO]BENZENESULFONAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; POTASSIUM CHANNEL HERG; QUETIAPINE; SERTRALINE; TERIKALANT; TOBORINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; ELECTROCARDIOGRAM; ENZYME INHIBITION; EXTRAPYRAMIDAL SYNDROME; GENE FUNCTION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MYOCARDITIS; NONHUMAN; OBESITY; PATIENT MONITORING; POTASSIUM CURRENT; PSYCHOPHARMACOLOGY; QRS COMPLEX; QT INTERVAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SLEEP APNEA SYNDROME; SUDDEN DEATH; TARDIVE DYSKINESIA; TORSADE DES POINTES;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; ITALY; POTASSIUM CHANNELS, VOLTAGE-GATED; TORSADES DE POINTES;

EID: 12344304103     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357055272     Document Type: Review

References (101)

1. Adamantidis, M. M., Kerram, P., Dupuis, B. A. (1994) In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fund. Clin. Pharmacol. 8: 391-407
2. Ban, T. A., Stjean, A. (1964) The effect of phenothiazines on the electrocardiogram. Can. Med. Assoc. J. 91: 537-540
3. Bastecky, J., Kvasnicka, J., Vortel, J., Zapletalek, M., Hanus, M., Kasparova, V., Wasylisova, V. (1990) Suicidal ingestion of thioridazine as a cause of severe impairment of heart rhythm - polymorphic ventricular tachycardia. Cesk. Psychiatr. 86: 264-268
4. Biswas, A. K., Zabrocki, M. D., Mayes, K., Morris-Kukoski, C. (2003) Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J. Toxic. Clin. Toxicol. 41: 79-82
5. Burton, S., Heslop, K., Harrison, K., Barnes, M. (2000) Ziprasidone overdose. Am. J. Psychiatry 157: 835
6. Committee for Proprietary Medicinal Products (1997) Points to Consider, CPMP/986/96, The European Agency for the Evaluation of Medicinal Products
7. Committee on Safety of Medicines - Medicines Control Agency (1995) Cardiac arrhythmias with pimozide (Orap). Current Problems in Pharmacovigilance 21: 1
8. Committee on Safety of Medicines - Medicines Control Agency (2001) Current Problems in Pharmacovigilance 27: 1-8
9. Czekalla, J., Beasley, C. M. Jr., Dellva, M. A., Berg, P. H., Grundy, S. (2001a) Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J. Clin. Psychiatry 62: 191-198
10. Czekalla, J., Kollack-Walker, S., Beasley, C. M. Jr. (2001b) Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J. Clin. Psychiatry 62: 35-40
11. Dershwitz, M. (2002) Droperidol: should the black box be light gray? J. Clin. Anesth. 14: 598-603
12. Desta, Z., Kerbusch, T., Flockhat, D. A. (1999) Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P4502D6 (CYP2D6). Clin. Pharmacol. Ther. 65: 10-20
13. Dineen, S., Withrow, K., Voronovitch, L., Munshi, F., Nawbary, M. W., Lippmann, S. (2003) QTc prolongation and high-dose olanzapine. Psychosomatics 44: 174-175
14. Donatini, B., Le Blaye, I., Krupp, P. (1992) Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine. Cardiology 81: 340-341
15. Drici, M. D., Wang, W. X., Liu, X. K., Woosley, R. L., Flockhart, D. A. (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J. Clin. Psychopharmacol. 18: 477-481
16. Drolet, B., Vincent, F., Rail, J., Chahine, M., Deschenes, D., Nadeau, S., Khalifa, M., Hamelin, B. A., Turgeon, J. (1999) Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed-rectifier potassium current. J. Pharmacol. Exp. Ther. 288: 1261-1268
17. Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Simard, C., Turgeon, J. (2001) Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J. Cardiovasc. Pharmacol. Ther. 6: 255-260
18. Duffy, P. A., Davis, A. S., Knight, R., Patmore, L., Templeton, A. (2001) Preclinical in vitro investigations of the effects of quetiapine and other atypical antipsychotics on cardiac QT interval. Eur. Neuropsychopharmacol. 11 (suppl. 3): S264
19. Eckardt, L., Breithardt, G., Haverkamp, W. (2002) Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J. Pharmacol. Exp. Ther. 300: 64-71
20. Fayer, S. A. (1986) Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J. Clin. Psychopharmacol. 6: 375-376
21. Finlayson, K., Turnbull, L., January, C. T., Sharkey, J., Kelly, J. S. (2001) [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur. J. Pharmacol. 430: 147-148
22. Food and Drug Administration (1996) Psychopharmacological Drug Advisory Committee, Sertindole NDA 20-644, Rockville MD
23. Food and Drug Administration (2000a) Ziprasidone Transcripts, Center for Drug Evaluation and Research, Psychopharmacological Drugs Advisory Committee, Rockville MD
24. Food and Drug Administration (2000b) Briefing Document for Zeldox Capsules (Ziprasidone), New York, Pfizer Inc., July 18, p 116
25. Food and Drug Administration (2001) Safety alerts for drugs, biologies, medical devices and dietary supplements, December 21
26. Fritze, J., Bandelow, B. (1998) The QT interval and the atypical antipsychotic, sertindole. Int. J. Psychiatr. Clin. Pract. 2: 265-273
27. Frust, B. A., Champion, M. K., Pierre, J. M., Wirhing, D. A., Wirshing, W. C. (2002) Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol. Psychiatry 51: 264-265
28. Gajwani, P., Pozuelo, L., Tesar, G. E. (2000) QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41: 63-65
29. Giles, T. D., Modlin, R. K. (1968) Death associated with ventricular arrhythmia and thioridazine hydrochloride. JAMA 205: 108-110
30. Glassman, A. H., Bigger, J. H. (2001) Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am. J. Psychiatry 158: 1774-1782
31. Gluais, P., Bastide, M., Caron, J., Adamantidis, M. (2002) Risperidone prolongs cardiac action potential through reduction of K+ currents in rabbit myocytes. Eur. J. Pharmacol. 444: 123-132
32. Gralinski, M. R. (2000) The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. J. Pharmacol. Toxicol. Methods 43: 91-99
33. Grohmann, R., Ruther, E., Sesim, N., Schmidt, L. G. (1989) Adverse effects of clozapine. Psychopharmacology 99: S101-104
34. Gupta, S., Nienhaus, K., Shah, S. A. (2003) Quetiapine and QTc issues: a case report. J. Clin. Psychiatry 64: 612-613
35. Gurovich, I., Vempaty, A., Lippmann, S. (2003) QTc prolongation: chlorpromazine and high-dosage olanzapine. Can. J. Psychiatry 48: 348
36. Guy, J. M., Andre-Fouet, X., Porte, J., Bertrand, M., Lamaud, M., Verneyre, H. (1991) Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol. Ann. Cardiol. Angeiol. 40: 541-545
37. Hamlin, R. L., Cruze, C. A., Mittelstadt, S. W., Kijtawornrat, A., Keene, B. W., Roche, B. M., Nakayama, T., Nakayama, H., Hamlin, D. M., Arnold, T. (2004) Sensitivity and specificity of isolated perfused guinea-pig heart to test for drug-induced lengthening of QTc. J. Pharmacol. Toxicol. Methods 49: 15-23
38. Harmon, T. J., Benitez, J. G., Krenzelok, E. P., Cortes-Belen, E. (1998) Loss of consciousness from acute quetiapine overdosage. J. Toxicol. 36: 599-602
39. Hatta, K., Takahashi, T., Nakamura, H., Yamashiro, H., Asukai, N., Matsuzaki, I., Yonezawa, Y. (2001) The association between intravenous haloperidol and prolonged QT interval. J. Clin. Psychopharmacol. 21: 257-261
40. Henderson, R. A., Lane, S., Henry, J. A. (1991) Life-threatening ventricular arrythmia (torsades de pointes) after haloperidol overdose. Hum. Exp. Toxicol. 10: 59-62
41. House, M. (2002) Overdose of ziprasidone. Am. J. Psychiatry 159: 1061-1062
42. Hulisz, D. T., Dasa, S. L., Black, L. D., Heiselman, D. E. (1994) Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 14: 239-245
43. Hunt, N., Stern, T. A. (1995) The association between intravenous haloperidol and torsades de pointes: three cases and a literature review. Psychosomatics 36: 541-549
44. Iglesias, E., Esteban, E., Zabala, S., Gascon, A. (2000) Tiapride-induced torsade de pointes. Am. J. Med. 109: 509
45. Jarchowsky, J., Zamin, D., Plavnik, L. (1991) Torsade de pointes and use of phenothiazine and diuretic. Harefuah 121: 435-436
46. Kang, U. G., Kwon, J. S., Ahn, Y. M., Chung, S. J., Ha, J. H., Koo, Y. J., Kim, Y. S. (2000) Electrocardiographic abnormalities in patients treated with clozapine. J. Clin. Psychiatry 61: 441-446
47. Kelly, H. G., Fay, J. E., Laverty, S. G. (1963) Thioridazine hydrochloride (Melleril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can. Med. Assoc. J. 89: 546-554
48. Klimke, A., Klieser, E. (1994) Sudden death after intravenous administration of lorazepam in a patient treated with clozapine. Am. J. Psychiatry 15: 780
49. Ko, P. T., Gulamhusein, S., Kostuk, W. J., Klein, G. J. (1982) Torsades de pointes, a common arrhythmia, induced by medication. Can. Med. Assoc. J. 127: 368-372
50. Kongsamut, S., Kang, J., Chen, X. L., Roehr, J., Rampe, D. (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450: 37-41
51. Krahenbuhl, S., Sauter, B., Kupferschmidt, H., Krause, M., Wyss, P. A., Meier, P. J. (1995) Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am. J. Med. Sci. 309: 315-316
52. Kriwisky, M., Perry, G. Y., Tarchitsky, D., Gutman, Y., Kishon, Y. (1990) Haloperidol-induced torsades de pointes. Chest 98: 482-484
53. La Grenade, L., Graham, D., Trontel, A. (2001) Myocarditis and cardiomyopathy associated with clozapine use in the United States. N. Engl. J. Med. 345: 224-225
54. Lande, G., Drouin, E., Gautheir, C., Chevallier, J. C., Godin, J. F., Chiffoleau, A., Le Marec, H. (1992) Arrhythmogenic effects of sultiproide chlorhydrate: clinical and cellular electrophysiological correlation. Ann. Fr. Anesth. Reanim. 11: 629-635
55. Lande, G., Demolombe, S., Bammert, A., Moorman, A., Charpentier, F., Escande, D. (2000) Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: pharmacological profile. Cardiovasc. Res. 50: 328-334
56. Lande, G., Demolombe, S., Bammert, A., Moorman, A., Charpentier, F., Escande, D. (2001) Transgenic mice overexpressing human KvLQT1 dominant-negative isoform Part II: pharmacological profile. Cardiovasc. Res. 50: 328-334
57. Lawrence, K. R., Nasraway, S. A. (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17: 531-537
58. Lewis, R., Bagnall, A., Leitner, M. (2000) Sertindole for schizophrenia. Cochrane Database Syst. Rev. CD001715
59. Liberatore, M. A., Robinson, D. S. (1984) Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? J. Clin. Psycopharmacol. 4: 143-148
60. Lischke, V., Behne, M., Doelken, P., Schledt, U., Probst, S., Vettrmann, J. (1994) Droperidol causes a dose-dependent prolongation of the QT interval. Anesth. Analg. 79: 983-986
61. Mack, R., Driscoll, R., Silber, C. (2002) The long term cardiovascular safety of sertindole. Eur. Neuropsychopharmacol. 7: S207
62. Michalets, E. L., Smith, L. K., Van Tassel, E. D. (1998) Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann. Pharmacother. 32: 761-765
63. Montez, L., Varache, N., Harry, P., Aymes, C., Turcant, A., Delille, F., Simonin, D., Hass, C. (1992) Torsades de pointes during sultopride poisoning. J. Toxicol. Clin. Exp. 12: 481-486
64. Nagaraja, D. S., Howard, S. R., Desmond, P., James, E. T. (1998) Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am. J. Cardiology 81: 238-240
65. Nudelman, E., Vinuela, L. M., Cohen, C. I. (1998) Safety in overdose of quetiapine: a case report. J. Clin. Psychiatry 59: 433
66. O'Brein, J. M., Rockwood, R. P., Suh, K. I. (1999) Haloperidol-induced torsade de pointes. Ann. Pharmacother. 33: 1046-1050
67. Ochiai, H., Kashiwagi, M., Usui, T., Oyama, Y., Tokita, Y., Ishikawa, T. (1990) Torsade de pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case. Kokyu To Junkan 38: 819-822
68. Osypenko, V. M., Degtiar, V., Naidonov, V. G., Shuba, I. M. (2001) Blockade of HERG K+ channels expressed in Xenopus oocytes by antipsichotic agents. Fiziol. Zh. 47: 17-25
69. Perrault, L. P., Denault, A. Y., Carrier, M., Cartier, R., Belisle, S. (2000) Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can. J. Anaesth. 47: 251-254
70. Physicians' Desk Reference (2000a) 54th edn, Medical Economics, Montvale, NJ, pp 562-566
71. Physicians' Desk Reference (2000b) 54th edn, Medical Economics, Montvale, NJ, pp 1453-1457
72. Pollak, P. T., Zbuk, K. (2000) Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin. Pharmacol. Ther. 68: 92-97
73. Raehl, C. I., Patel, A. K., Le Roy, M. (1985) Drugs-induced torsade de pointes. Clin. Pharm. 4: 675-690
74. Rampe, D., Murawsky, M. K., Gran, J., Lewis, E. W. (1998) The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J. Pharmacol. Exp. Ther. 286: 788-793
75. Ravin, D. S., Levenson, J. W. (1997) Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. 31: 867-870
76. Sharma, N. D., Rosman, H. S., Padhi, I. D., Tisdale, J. E. (1998) Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am. J. Cardiol. 81: 238-240
77. Shuba, Y. M., Degtiar, V. E., Osypenko, V. N., Naidenov, V. G., Woosley, R. L. (2001) Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem. Pharmacol. 62: 41-49
78. Steele, J. W., Faulds, D., Sorkin, E. M. (1993) Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation. Drugs Aging 3: 460-478
79. Studenik, C., Lemmens-Gruber, R., Heistracher, P. (1998) Proarrhythmic effects of antidepressant and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibres. Eur. J. Pharmac. Sci. 7: 113-118
80. Su, K. P., Shen, W. W., Choung, U. L., Chen, K. P. (2003) A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophr. Res. 59: 93-94
81. Suessbrich, H., Schonnherr, R., Heinemann, S. H., Attali, B., Lang, F., Busch, A. E. (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br. J. Pharmacol. 120: 968-974
82. Sugiyama, A. (2003) Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models. Nippon Yakurigaku Zasshi 121: 393-400
83. Sugiyama, A., Satoh, Y., Shiina, H., Takeda, S., Hashimoto, K. (2002) Torsadogenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J. Cardiovasc. Pharmacol. 40: 235-245
84. Takeda, S., Takano, H., Obata, J. (2001) Arrhythmogenic effects of sulpiride: a clinical case report and canine experimental study. J. Mol. Cell. Cardiol. 33: A118
85. Tamargo, J. (2000) Drug-induced torsade de pointes: from molecular biology to bedside. Jpn. J. Pharmacol. 83: 1-19
86. Teasdel, G., Jannet, B. (1974) Assessment of coma and impaired consciousness: a practical scale, Lancet 2: 81-84
87. Teich, J. (2003) Side effects of ziprasidone. Am. J. Psychiatry 160: 1355-1356
88. Testai, L., Calderone, V., Salvadori, A., Breschi, M. C., Nieri, P., Martinotti, E. (2004) QT prolongation in anaesthetised guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug-candidates. J. Appl. Toxicol. 24: 217-222
89. Thomas, S. H. (1994) Drugs, QT interval abnormalities and ventricular arrythmias. Adverse Drug React. Toxicol. Rev. 13: 77-102
90. Thomas, D., Wu, K., Kathofer, S., Katus, H. A., Schoels, W., Kiehn, J., Karle, C. A. (2003) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol. 139: 567-574
91. Thomsen, M. B., Volders, P. G. A., Stengl, M., Spatjens, R. L. H. M., Beekman, J. D., Biscoff, U., Kail, M. A., Frederiksen, K., Matz, J., Vos, M. A. (2003) Electrophysiological safety of sertindole in drugs with normal and remodeled hearts. J. Pharmacol. Exp. Ther. 307: 776-784
92. Tisdale, J. E., Rasty, S., Padhi, I. D., Sharma, N. D., Rosman, H. (2001) The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J. Clin. Pharmacol. 41: 1310-1318
93. Titier, I., Deridet, E., Moore, N. (2002) In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone. Toxicol. Appl. Pharmacol. 180: 145-149
94. Toumi, M. (2002) Post-marketing surveillance of sertindole. Int. J. Psychiatry Clin. Pract. 6: S33-S35
95. Viskin, S., Justo, D., Halkin, A., Zeltser, D. (2003) Long QT syndrome caused by noncardiac drugs. Prog. Cardiovasc. Dis. 45: 415-427
96. Warner, J. P., Barnes, T. R. E., Henry, J. A. (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr. Scand. 93: 311-313
97. Wilson, W. H., Weiler, S. J. (1984) Case report of phenothiazine-induced torsade de pointes. Am. J. Psychiatry 141: 1265-1266
98. Wilt, J. L., Minnema, A. M., Jonson, R. F., Rosenblum, A. M. (1993) Torsade de pointes associated with the use of intravenous haloperidol. Ann. Intern. Med. 119: 391-394
99. Wilton, L. V., Heeley, E. L., Pickering, R. M., Shakir, S. A. (2001) Comparative study of mortality rates and cardiac dysarhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J. Psychopharmacol. 15: 120-126
100. www.fenichel.net/pages/Professional/subpages/QT/Tables/pbydrug.htm
101. www.hc-sc.gc.Ca/hpb-dgps/therapeut/zfiles/english/notices/mellaril_e.pdf